<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JCHEM</journal-id><journal-title-group><journal-title>Journal of Chemistry</journal-title></journal-title-group><issn pub-type="epub">2090-9071</issn><issn pub-type="ppub">2090-9063</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2020/3928204</article-id><article-id pub-id-type="publisher-id">3928204</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Synthesis of Phthalimide Imine Derivatives as a Potential Anticancer Agent</article-title></title-group><contrib-group><contrib contrib-type="author" id="U25942564"><name><surname>Abdulrahman</surname><given-names>Hayman Sardar</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author" id="U13568979"><name><surname>Hassan Mohammed</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author" id="U87145730"><name><surname>Al-Ani</surname><given-names>Lina A.</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author" id="U21387564"><name><surname>Ahmad</surname><given-names>Mohd Hafiz</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author" id="U27831368"><name><surname>Hashim</surname><given-names>Najihah M.</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref><xref ref-type="aff" rid="I5"><sup>5</sup></xref></contrib><contrib contrib-type="author" id="U56954964" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1543-9887</contrib-id><name><surname>Yehye</surname><given-names>Wageeh A.</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="Academic Editor" id="U10595328"><name><surname>Navarrete-Vazquez</surname><given-names>Gabriel</given-names></name></contrib></contrib-group><aff id="I1"><sup>1</sup><addr-line>Department of Pharmaceutical Chemistry</addr-line><addr-line>Pharmacy College</addr-line><addr-line>Hawler Medical University</addr-line><addr-line>Erbil</addr-line><addr-line>Kurdistan Region</addr-line><country>Iraq</country><ext-link ext-link-type="domain-name">hmu.edu.iq</ext-link></aff><aff id="I2"><sup>2</sup><addr-line>Department of Pharmaceutical Chemistry</addr-line><addr-line>Pharmacy College</addr-line><addr-line>University of Baghdad</addr-line><addr-line>Baghdad</addr-line><country>Iraq</country><ext-link ext-link-type="domain-name">uobaghdad.edu.iq</ext-link></aff><aff id="I3"><sup>3</sup><addr-line>Nanotechnology &#x26; Catalysis Research Centre (NANOCAT)</addr-line><addr-line>Institute for Advanced Studies</addr-line><addr-line>Block 3a</addr-line><addr-line>University of Malaya</addr-line><addr-line>Kuala Lumpur 50603</addr-line><country>Malaysia</country><ext-link ext-link-type="domain-name">um.edu.my</ext-link></aff><aff id="I4"><sup>4</sup><addr-line>Department of Pharmaceutical Chemicals</addr-line><addr-line>Faculty of Pharmacy</addr-line><addr-line>University of Malaya</addr-line><addr-line>Kuala Lumpur</addr-line><country>Malaysia</country><ext-link ext-link-type="domain-name">um.edu.my</ext-link></aff><aff id="I5"><sup>5</sup><addr-line>Centre for Natural Products and Drug Discovery (CENAR)</addr-line><addr-line>University of Malaya</addr-line><addr-line>Kuala Lumpur</addr-line><country>Malaysia</country><ext-link ext-link-type="domain-name">um.edu.my</ext-link></aff><pub-date pub-type="publication-year"><year>2020</year></pub-date><pub-date pub-type="archival-date"><day>16</day><month>9</month><year>2020</year></pub-date><volume>2020</volume><history><date date-type="received"><day>24</day><month>05</month><year>2020</year></date><date date-type="accepted"><day>17</day><month>08</month><year>2020</year></date><date date-type="pub"><day>16</day><month>9</month><year>2020</year></date></history><permissions><copyright-year>2020</copyright-year><copyright-holder>Copyright &#xa9; 2020 Hayman Sardar Abdulrahman et al.</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The outstanding evidence of phthalimide pharmacophore in securing enhanced biological activities had encouraged further research and development into phthalimide-based derivatives as potential new drugs. In this study, phthalimide core was hybridized with aldehydes giving integrated imines displaying different types of functionalities and at alternating positions. The resulting compounds, therefore, provide an innovative window to explore possible differential biological effects as antioxidants and anticancer agents. A total of sixteen compounds were synthesized, and each was verified by FT-IR, H NMR, C NMR, and MS characterization. Herein, a facile single-step synthesis method was employed substituting the conventional two-step chemical production routes. Among the sixteen tested compounds, the H7 compound with hydroxyl phenolic group has shown an eminent antioxidant activity with a 19.52&#x0025; decrease to the IC<sub>50</sub> value compared to that of the control standard BHT antioxidant. On the other hand, the halogenated H6 Schiff base structure was successful in securing effective cancer inhibition to both colon and breast cancer cell lines, while maintaining selective action toward normal tissues. Results have collectively indicated the importance and impactful effects of functional groups position and types within similar basic structures, in directing different biological outcomes.</p></abstract><funding-group><award-group><funding-source xlink:href="http://dx.doi.org/10.13039/501100004386">Universiti Malaya</funding-source><award-id>RP044C-17AET</award-id></award-group></funding-group><counts><fig-count count="4" /><table-count count="3" /><ref-count count="50" /><page-count count="13" /></counts></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>The current pursue of innovative, biological-active chemicals continues to occupy a major part in medicinal chemistry and drug development research, in hope for beneficial, safer, and more potent outcomes than available medications [<xref ref-type="bibr" rid="B1">1</xref>]. Antioxidant and anticancer potentials represent two of the most widely searched biological activities targeting various disease types including cancer [<xref ref-type="bibr" rid="B2">2</xref>&#x2013;<xref ref-type="bibr" rid="B4">4</xref>]. It is now clear that conventional therapies of chemotherapy and radiotherapy are not the definite answer for a selective cancer cure, and accordingly, the high mortality rates were maintained during the recent decades (WHO, 2018). This, in turn, necessitates the development of novel therapies [<xref ref-type="bibr" rid="B5">5</xref>]. Antioxidants, on the other hand, have been evidence-based to aid in the treatment and/or prevention of numerous diseases, especially those with etiology related to redox-state imbalances [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. Herein, phthalimide derivatives have been the focus in an increasing number of studies recently [<xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>]. The&#x2013;CO-N(R)-CO structural feature connection to the imide ring in phthalimide chemical had proven immense biological impacts as antimicrobial [<xref ref-type="bibr" rid="B8">8</xref>], anti-inflammatory, antiviral, and anticancer activities [<xref ref-type="bibr" rid="B12">12</xref>]. The hydrophobic characteristics, as one example to the point, enable membrane interaction and improve bioavailability, which explains phthalimide use as a starting material for the synthesis of various pharmacophores [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B13">13</xref>].</p><p>The rational hybridization of phthalimide core to different functionalities further widens possible application areas [<xref ref-type="bibr" rid="B14">14</xref>]. In this field, the derivatives of phthalimide-Schiff bases demonstrated multiple strengths in different biological processes [<xref ref-type="bibr" rid="B14">14</xref>]. The nitrogen atom of imine (-C&#x3d;N-) Schiff base group is thought to involve in hydrogen bonding with several cellular constituents [<xref ref-type="bibr" rid="B15">15</xref>] which can modulate activities and processes. Published data have indicated the promising avenues explored to date for hybridized phthalimide-Schiff base structures [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. However, the complex multistep synthesis procedures, along with the low yield and high cost, are recognized as challenging factors [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. In addition, different biological effects were observed in response to varying structures [<xref ref-type="bibr" rid="B20">20</xref>]. In this work, we aim to exploit both of phthalimide ring and Schiff base biological potentials into designing various hybridized structures, while innovatively altering attached functional groups in terms of types and positions, in relation to commonly tested derivatives [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B21">21</xref>]. A total of 16 compounds were synthesized using one-step N-aminophthalimide hybridization with functionalized aldehydes. Resulted compounds displayed a wide variety of groups pertaining to halogens, methoxy groups, phenolics, among others, which are known for biological interaction possibilities [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. The alteration in types and positions of these groups within compounds is anticipated to reveal new perspectives in exploring possible differential biological outcomes. Physicochemical properties are also investigated along with antioxidant activity and cancer cytotoxicity, as potential biological activities. Distinctly, safety profile and selectivity of the synthesized imines are also explored using respective normal cell lines, in a step forward to comply with the recent up-to-date toxicology research and recommendations [<xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec id="sec2"><title>2. Results</title><sec id="sec2.1"><title>2.1. Chemistry</title><p>The synthetic route used in this study to obtain hybridized compounds labeled H1 through H16 is illustrated in Figure <xref ref-type="fig" rid="fig1">1</xref>, while the final compounds&#x2019; structures are presented in Table <xref ref-type="table" rid="tab1">1</xref>.</p><fig id="fig1"><label>Figure 1</label><caption><p>General synthesis route for N-aminophthalimide derivatives.</p></caption><graphic xlink:href="3928204.fig.001" /></fig><table-wrap id="tab1"><label>Table 1</label><caption><p>Imines design and hybridization structures.</p></caption><table><thead><tr><th align="left">Target compound</th><th align="center">Hybridized aldehyde</th><th align="center">Schiff base structure</th></tr></thead><tbody><tr><td align="left">H1</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.001" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.002" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H2</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.003" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.004" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H3</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.005" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.006" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H4</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.007" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.008" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H5</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.009" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0010" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H6</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0011" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0012" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H7</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0013" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0014" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H8</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0015" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0016" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H9</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0017" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0018" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H10</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0019" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0020" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H11</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0021" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0022" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H12</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0023" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0024" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H13</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0025" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0026" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H14</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0027" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0028" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H15</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0029" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0030" /></td></tr><tr><td align="left" colspan="3"><hr /></td></tr><tr><td align="left">H16</td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0031" /></td><td align="center"><inline-graphic xlink:href="3928204.tab-inline.0032" /></td></tr></tbody></table></table-wrap><p>Generally, the imine compounds are formed using two types of chemical reactions, i.e., addition and elimination (Figure <xref ref-type="fig" rid="fig2">2</xref>). It must be noted that the acid concentration must be low since the amines were basic compounds [<xref ref-type="bibr" rid="B27">27</xref>].</p><fig id="fig2"><label>Figure 2</label><caption><p>Reaction mechanism for N-aminophthalimide derivatives synthesis.</p></caption><graphic xlink:href="3928204.fig.002" /></fig><p>The structures of final imines were confirmed by FT-IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, and high-resolution mass spectra as described in the Methods section (full spectra data of FT-IR, <sup>1</sup>H-NMR, and <sup>13</sup>C-NMR can be found in Supplementary Figures through Section <xref ref-type="sec" rid="supplementary-material-1">1</xref>&#x2013;Section <xref ref-type="sec" rid="supplementary-material-1">3</xref>). The IR spectra of compounds H5, H7, and H8, bearing the O-H group, showed absorption peaks at 3328, 3317, and 3319&#x2009;cm<sup>&#x2212;1</sup>, respectively. Compounds H1&#x2013;H16 showed absorption band(s) at regions between 3099 and 2918&#x2009;cm<sup>&#x2212;1</sup> due to C-H of the ring and C-H of CH<sub>3</sub> for compounds H3, H7&#x2013;H10, and H14&#x2013;H16. Compound H9, the only compound having cyano-functional group (C&#x2261;N), showed an absorption peak at 2252&#x2009;cm<sup>&#x2212;1</sup>. Each compound shows an absorption peak at 1719&#x2013;1707 cm<sup>&#x2212;1</sup>, 1641&#x2013;1598 cm<sup>&#x2212;1</sup>, 1596&#x2013;1481 cm<sup>&#x2212;1</sup>, and 1314&#x2013;1297 cm<sup>&#x2212;1</sup> due to (C&#x3d;O), (C&#x3d;N), (C&#x3d;C), and (C-N), respectively. Compound H2, the single compound among the synthesized compounds with (C-O) bond in the furfural ring, showed an absorption peak at 1113&#x2009;cm<sup>&#x2212;1</sup>. Compounds that present ether in their structures showed absorption peaks at 1115 and 1085 cm<sup>&#x2212;1</sup>, 1105 and 1083 cm<sup>&#x2212;1</sup>, 1116 and 1081 cm<sup>&#x2212;1</sup>, and 1119 and 1081 cm<sup>&#x2212;1</sup> for compounds H7, H10, H14, and H15, respectively.</p><p>The <sup>1</sup>H-NMR spectra of compounds H1&#x2013;H16 showed a multiplate peak between 7.69 and 7.95&#x2009;ppm for proton on carbon 4, 7.68&#x2013;7.95&#x2009;ppm for proton on carbon 5 and 6, and 7.69&#x2013;7.94&#x2009;ppm for proton on carbon 7. All compounds showed a singlet peak in the region between 8.68 and 9.82 ppm, due to a single proton at benzylidene carbon (CH&#x3d;N). Compounds H5 and H7 have hydroxyl functional group, and compound H5 <sup>1</sup>H-NMR gives a singlet peak at 11.13&#x2009;ppm, due to the phenolic OH bonded to carbon 4<sup>\\</sup>. In contrast to compound H5, the phenolic OH of compound H7, which is linked to carbon 4<sup>\\</sup>, which was also surrounded by two methoxy groups, is significantly shielded to 5.81&#x2009;ppm due to greater steric effect between two bulky groups than that of compound H5. The <sup>13</sup>C-NMR spectra of compounds H1&#x2013;H16 indicated the presence of one sp<sup>2</sup> methine shifts between 140.60 and 159.93&#x2009;ppm.</p></sec><sec id="sec2.2"><title>2.2. Biological Activities</title><sec id="sec2.2.1"><title>2.2.1. Antioxidant Activity</title><p>The antioxidant activity of the synthesized compounds was evaluated using DPPH free radical inhibition assay. Results reveal a concentration-dependent trend among all synthesized imines (Supplementary Figure <xref ref-type="sec" rid="supplementary-material-1">S4</xref>), while Table <xref ref-type="table" rid="tab2">2</xref> lists the respective DPPH scavenging activity in terms of IC<sub>50</sub> values (mean&#x2009;&#xb1;&#x2009;SEM). Compound H7 scored the highest antioxidant activity among other active compounds as shown in Figure <xref ref-type="fig" rid="fig3">3</xref>, with an IC<sub>50</sub> value of 28.37&#x2009;&#xb1;&#x2009;0.89&#x2009;<italic>&#xb5;</italic>M, surpassing that of standard antioxidant BHT (IC<sub>50</sub> 35.25&#x2009;&#xb1;&#x2009;1.08&#x2009;<italic>&#xb5;</italic>M).</p><table-wrap id="tab2"><label>Table 2</label><caption><p>IC<sub>50</sub> values of DPPH free radical scavenging activity of imines.</p></caption><table><thead><tr><th align="left">Compound</th><th align="center">Scavenging activity DPPH (IC<sub>50</sub><italic>&#xb5;</italic>M&#x2009;&#xb1;&#x2009;SEM)</th></tr></thead><tbody><tr><td align="left">H1</td><td align="center">NA</td></tr><tr><td align="left">H2</td><td align="center">NA</td></tr><tr><td align="left">H3</td><td align="center">NA</td></tr><tr><td align="left">H4</td><td align="center">NA</td></tr><tr><td align="left">H5</td><td align="center">546.43&#x2009;&#xb1;&#x2009;0.96</td></tr><tr><td align="left">H6</td><td align="center">NA</td></tr><tr><td align="left">H7</td><td align="center">28.37&#x2009;&#xb1;&#x2009;0.89</td></tr><tr><td align="left">H8</td><td align="center">NA</td></tr><tr><td align="left">H9</td><td align="center">NA</td></tr><tr><td align="left">H10</td><td align="center">NA</td></tr><tr><td align="left">H11</td><td align="center">NA</td></tr><tr><td align="left">H12</td><td align="center">NA</td></tr><tr><td align="left">H13</td><td align="center">NA</td></tr><tr><td align="left">H14</td><td align="center">NA</td></tr><tr><td align="left">H15</td><td align="center">NA</td></tr><tr><td align="left">H16</td><td align="center">NA</td></tr><tr><td align="left">N-Aminophthalimide</td><td align="center">NA</td></tr><tr><td align="left">BHT</td><td align="center">35.25&#x2009;&#xb1;&#x2009;1.08</td></tr></tbody></table><table-wrap-foot><fn><p>NA: not applicable (above testing range).</p></fn></table-wrap-foot></table-wrap><fig id="fig3"><label>Figure 3</label><caption><p>DPPH free radical inhibition percentage of selected active imines compounds and the starting material N-aminophthalimide.</p></caption><graphic xlink:href="3928204.fig.003" /></fig></sec><sec id="sec2.2.2"><title>2.2.2. <italic>In Vitro</italic> Anticancer Activity</title><p>The chemotherapeutic potential of the synthesized imines was screened against four human <italic>in vitro</italic> cell lines, representing colon and breast cancer cells (HT-29 and MCF-7), along with the normal tissue counterparts (CCD-841 and MCF-10A) cells. The panel uses 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay that measures cellular mitochondrial activity as dictating factor for healthy, metabolically active cells [<xref ref-type="bibr" rid="B28">28</xref>], upon treatment with compound&#x2019;s various concentrations for 24-hour incubation time. Selectivity ratios were also calculated and expressed as selectivity index (SI) for each compound in colon and breast tissues. Results revealed a concentration-dependent anticancer activity for the majority of compounds (full data presented in Supplementary Figures <xref ref-type="sec" rid="supplementary-material-1">S5</xref>-<xref ref-type="sec" rid="supplementary-material-1">S6</xref>), while the respective IC<sub>50</sub> and SI values are presented in Table <xref ref-type="table" rid="tab3">3</xref>, demonstrating variable effects among colon and breast cancer types. The highest cancer-active compound trends are displayed in Figure <xref ref-type="fig" rid="fig4">4</xref>, in comparison to the starting material (N-aminophthalimide) activities. In colon cancer, various imines displayed lower IC<sub>50</sub> values compared to the precursor chemical N-aminophthalimide. Compounds H6, H7, and H10 recorded the lowest IC<sub>50</sub> values along with concurrent acceptable SI threshold. On the other hand, H6 and H14 compounds were most active and safe against breast cancer tissue.</p><table-wrap id="tab3"><label>Table 3</label><caption><p>IC<sub>50</sub> values and selectivity indices (SI) of cancer cells treated with imines compounds.</p></caption><table><thead><tr><th align="left">Sample</th><th align="center">HT-29 colon cancer (IC<sub>50</sub>&#x2009;&#xb1;&#x2009;SEM, <italic>&#xb5;</italic>M), SI</th><th align="center">MCF-7 Breast cancer (IC<sub>50</sub>&#x2009;&#xb1;&#x2009;SEM, <italic>&#xb5;</italic>M), SI</th></tr></thead><tbody><tr><td align="left">H1</td><td align="center">(643.7&#x2009;&#xb1;&#x2009;9.8), 1.24</td><td align="center">NA</td></tr><tr><td align="left">H2</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">H3</td><td align="center">(625.6&#x2009;&#xb1;&#x2009;34.2), 1.27</td><td align="center">NA</td></tr><tr><td align="left">H4</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">H5</td><td align="center">(544.5&#x2009;&#xb1;&#x2009;8.6), 1.46</td><td align="center">(585.5&#x2009;&#xb1;&#x2009;86.6), 1.36</td></tr><tr><td align="left">H6</td><td align="center">(253.6&#x2009;&#xb1;&#x2009;45.6), 3.16</td><td align="center">(293.0&#x2009;&#xb1;&#x2009;40.7), 2.73</td></tr><tr><td align="left">H7</td><td align="center">(277.6&#x2009;&#xb1;&#x2009;57.5), 2.88</td><td align="center">NA</td></tr><tr><td align="left">H8</td><td align="center">(666.9&#x2009;&#xb1;&#x2009;30.7), 1.20</td><td align="center">NA</td></tr><tr><td align="left">H9</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">H10</td><td align="center">(331.6&#x2009;&#xb1;&#x2009;6.2), 2.41</td><td align="center">NA</td></tr><tr><td align="left">H11</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">H12</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">H13</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">H14</td><td align="center">(466.9&#x2009;&#xb1;&#x2009;34.2), 1.69</td><td align="center">(325.2&#x2009;&#xb1;&#x2009;27.2), 2.46</td></tr><tr><td align="left">H15</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">H16</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">N-Aminophthalimide</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">Control drugs</td><td align="center">5-FU drug (80.6&#x2009;&#xb1;&#x2009;1.36), 2.03</td><td align="center">TMX drug: (20.24&#x2009;&#xb1;&#x2009;0.19), 1</td></tr></tbody></table><table-wrap-foot><fn><p>NA: not applicable (above testing range).</p></fn></table-wrap-foot></table-wrap><fig-group id="fig4"><label>Figure 4</label><caption><p>Anticancer activities of selected active imines. (a) Colon cancer HT-29 cell line viability. (b) Breast cancer MCF-7 cell line viability, after treatment with imines for 24 hours.</p></caption><fig id="fig4a"><label>(a)</label><graphic xlink:href="3928204.fig.004a" /></fig><fig id="fig4b"><label>(b)</label><graphic xlink:href="3928204.fig.004b" /></fig></fig-group></sec></sec></sec><sec id="sec3"><title>3. Discussion</title><p>The rational and concept of the design of this study are based on modifying phthalimide structure by molecular hybridization with various aldehydes. The phthalimide focal point was maintained during synthesis, while changing aldehydes functionalities in terms of types and position took place in the latter synthetic steps. It is proposed here that the integration of imine (-N&#x3d;C-) functional group with its broad biological activities on the one hand [<xref ref-type="bibr" rid="B15">15</xref>] and the various cancer inhibition potentials of phenolic functional groups on the other hand [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>] is the path to enhanced and possible differential biological activities.</p><p>The synthesized compounds&#x2019; structural properties were confirmed by FT-IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, and high-resolution mass spectra, as explained earlier. In relation to previous studies proving the presence of biological or industrial activities to similar phthalimide-derivative structures [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B21">21</xref>], we hypothesize that the presence of the same functional group at alternating positions (compounds H11, H12, and H13) or the different functionalities (compounds H5, H6, and H7) designates vital target and additional merits in measuring the possible differential biological activities which will aid in dictating the suitable application path. The antioxidant potential measured by DPPH free radical inhibition as the commonly used assay for chemicals screening [<xref ref-type="bibr" rid="B31">31</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>] revealed a relatively weak antioxidant activity of the precursor chemical N-aminophthalimide that was only enhanced after introducing imines hybridization, at compounds H7&#x2009;&#x3e;&#x2009;H5&#x2009;&#x3e;&#x2009;H1&#x2009;&#x3e;&#x2009;N-aminophthalimide (Figure <xref ref-type="fig" rid="fig3">3</xref>). In this regard, the relative higher antioxidant activity trends demonstrated especially in compounds H7 and H5 may reflect their structures containing particular antioxidant fragments, which are very important for antioxidant activity especially in a single structure; these include phenolic hydroxyl group, substituted phenyl to increase the free radical stabilization, electron-donating group, and imino group to extend free radical delocalization [<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>]. Additionally, the presence of methoxy substitutions is documented to further enhance the antioxidant efficiency of monophenols [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>The second line of biological activities&#x2019; measurement was dedicated to cancer treatment potentials. The high incidence and mortality rates imposed by this disease emphasize the vital role of chemicals&#x2019; development and design, with special care to the safety parameters. Reporting of early biocompatibility and selectivity signs toward normal tissue is now essential in exploring anticancer activities, and the recent toxicology reviews and recommendations call for such implementation that aid in obtaining a clear overview of studied agent potentials and pitfalls, leading to effective future translation into clinical use [<xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B26">26</xref>]. In this work, normal colon and breast cell lines were tested in parallel with malignant counterparts, through measuring selectivity index (SI). Results generally displayed varied compounds&#x2019; responses among colon and breast cancer cell lines, which may reflect the differential and heterogeneous cancer microenvironments affecting treatment outcomes, as documented previously [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>]. N-aminophthalimide demonstrated a concentration-dependent decrease in the viability of both cancer types, which agrees with previous reports stating potential anticancer activity of phthalimide pharmacophore (Figure <xref ref-type="fig" rid="fig4">4</xref>) [<xref ref-type="bibr" rid="B38">38</xref>]. Nevertheless, the effective and safe anticancer potency was only achievable after hybridization and the production of imine compounds (Table <xref ref-type="table" rid="tab3">3</xref>). Such remark confirms the enhanced anticancer action of the hybridized imines.</p><p>Among the tested compounds, the H6 Schiff base displayed the most potent anticancer activity in both colon and breast cancer cell lines. It is anticipated that its structure including two halogens, namely, bromine and fluorine, might be relevant to its anticancer activity [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B39">39</xref>&#x2013;<xref ref-type="bibr" rid="B41">41</xref>]. Herein, several studies have indicated the effective compounds&#x2019; bromination as a strategy to enhance biological properties and increase cytotoxicity, by targeting cellular nucleic acid production as one possible pathway among others [<xref ref-type="bibr" rid="B50">50</xref>]. The underlying mechanisms of these effects are still unclear; however, higher rates of lipophilicity, cellular permeability, and intermolecular bonds with biomolecules constitute probable explanatory axes [<xref ref-type="bibr" rid="B42">42</xref>]. On the other hand, fluorine has been reported to own the strongest hydrogen binding among halogens, which enable selective binding to specific proteins or enzymes, hence providing good anticancer activity [<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B43">43</xref>&#x2013;<xref ref-type="bibr" rid="B45">45</xref>]. The presence of a phenyl ring is also important to provide more lipophilic character, which is reported to own the potential to inhibit proteins for cell growth [<xref ref-type="bibr" rid="B46">46</xref>]. Variously, the presence of methoxy and hydroxyl groups in H7, H14, and H10 may enhance the anticancer activity [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B47">47</xref>]. Studies of cytotoxicity activity have demonstrated that electron releasing groups, especially at para position, will enhance cancer cytotoxicity [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B47">47</xref>]. In particular, H14 compound has displayed good anticancer activity against MCF-7 breast cancer cell line with an acceptable selectivity index, despite its high molecular weight and presence of two bulky groups, which might be thought to cause steric hindrance preventing interaction with cellular proteins, as reported previously [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. However, the active functional group, namely, the methoxy group at the ortho position, is expected to increase the compound&#x2019;s activity against the cancer cell environment.</p><p>In summary, this work highlights the differential biological outcomes within the synthesized compounds. Herein, some compounds displayed weak activity against used cancer cell lines, while they have the highest antioxidant potency and vice versa. This is related to the presence of phenolic and methoxy substitutions at aromatic imines that improve the antioxidant activity of phthalimide, while the presence of meta bromo and para fluoro substituted imines will improve the anticancer activity.</p></sec><sec id="sec4"><title>4. Materials and Methods</title><sec id="sec4.1"><title>4.1. Materials</title><p>All materials and solvents were purchased from commercial suppliers, including Thermo Fisher, Merck, and Sigma Aldrich and used without additional purification. Melting points (MPs) were determined on a MEL-TEMP II melting point instrument. Fourier Transform Infra-Red spectroscopy (FT-IR) was recorded on a PerkinElmer spectrum 400 FT-IR/FT-FIR spectrometer. The <sup>1</sup>H-NMR (600&#x2009;MHz) and <sup>13</sup>C-NMR (150&#x2009;MHz) spectra were recorded on BRUKER 600&#x2009;MHz spectrometer using CDCl<sub>3</sub> or DMSO as a solvent. High-resolution electron ionization mass spectrometry (HREIMS) <italic>m/z</italic> was obtained with LC/MS mass spectrometer.</p></sec></sec><sec id="sec5"><title>5. Methods</title><sec id="sec5.1"><title>5.1. General Synthesis of Imines</title><p>The N-aminophthalimide chemical was dissolved in ethanol, and then target aldehyde was added along with glacial acetic acid. The mixture was then refluxed for 6 hours at 78&#xb0;C, followed by using thin-layer chromatography TLC. After completion, the mixture was cooled down to room temperature (25&#xb0;C) and then kept at 4&#xb0;C for 1 hour, and the precipitate was collected, filtered, and recrystallized from ethanol to give a crystal product. Further specific details of synthesis can be found in <xref ref-type="sec" rid="supplementary-material-1">Supplementary Material</xref>.<list><list-item><label>(1)</label><p>(E)-2-(Benzylideneamino)isoindole-1,3-dione (H1): off-white crystal product of 0.57 gram (Yield 75&#x0025;); MP: 132&#x2013;135&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3048 (C&#x2013;H of ring), 1708 (C&#x3d;O), 1599 (C&#x3d;N), 1572 (C&#x3d;C), 1314 (C&#x2013;N). <sup>1</sup>H NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.94 (<italic>m</italic>, 1 H, H-4), 7.94 (<italic>m</italic>, 1 H, H-5), 7.94 (<italic>m</italic>, 1H, H-6), 7.94 (<italic>m</italic>, 1H, H-7), 9.42 (<italic>s</italic>, 1H, H-of benzylidene carbon), 7.80 (<italic>m</italic>, 1H, H-2<sup>\\</sup>), 7.49 (<italic>m</italic>, 1H, H-3<sup>\\</sup>), 7.49 (<italic>m</italic>, 1H, H-4<sup>\\</sup>), 7.49 (<italic>m</italic>, 1H, H-5<sup>\\</sup>), 7.80 (<italic>m</italic>, 1H, H-6<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.11 (2C, C-1, C-3), 131.69 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.78 (2C, C-4, C-7), 134.64 (2C, C-5, C-6), 158.65 (1C, C-benzylidene), 133.66 (1C, C-1<sup>\\</sup>), 128.78 (2C, C-2<sup>\\</sup>, C-6<sup>\\</sup>), 128.44 (2C, C-3<sup>\\</sup>, C-5<sup>\\</sup>), 130.36 (1C, C-4<sup>\\</sup>). HREIMS <italic>m/z</italic>: 251.0742 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>15</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub> 250.2570).</p></list-item><list-item><label>(2)</label><p>(E)-2-((Furan-2-ylmethylene)amino)isoindoline-1,3-dione (H2): A yellow powder product of 0.53 gram (Yield 72&#x0025;); MP: 139&#x2013;141&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3099 (C&#x2013;H of ring), 1715 (C&#x3d;O), 1607 (C&#x3d;N), 1481 (C&#x3d;C), 1299 (C&#x2013;N), 1113 (C&#x2013;O). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.85 (<italic>m</italic>, 1H, H-4), 7.71 (<italic>m</italic>, 1H, H-5), 7.71 (<italic>m</italic>, 1H, H-6), 7.85 (<italic>m</italic>, 1H, H-7), 9.25 (<italic>s</italic>, 1H, H-of benzylidene carbon), 6.92 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-2<sup>\\</sup>), 6.49 (<italic>m</italic>, 1H, H-3<sup>\\</sup>), 7.56 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-4<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 164.99 (2C, C-1, C-3), 146.01 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.82 (2C, C-4,C-7), 134.69 (2C, C-5, C-6), 148.95 (1C, C- benzylidene), 146.50 (1C, C-1<sup>\\</sup>), 116.82 (1C, C-2<sup>\\</sup>), 112.27 (1C, C-3<sup>\\</sup>), 130.28 (1C, C-4<sup>\\</sup>). HREIMS <italic>m/z</italic>: 241.0536 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>13</sub>H<sub>8</sub>N<sub>2</sub>O<sub>3</sub> 240.2180).</p></list-item><list-item><label>(3)</label><p>2-(((1E, 2E)-2-Methylbut-2-en-1-ylidene)amino)isoindoline-1,3-dione (H3): a milky woolly product of 0.26 gram (Yield 37&#x0025;); MP: 86&#x2013;88&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;2923 and 2857 (C&#x2013;H of ring and of CH<sub>3</sub>), 1707 (C&#x3d;O), 1634 (C&#x3d;N), 1573 (C&#x3d;C), 1309 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.82 (<italic>m</italic>, 1H, H-4), 7.68 (<italic>m</italic>, 1H, H-5), 7.68 (<italic>m</italic>, 1H, H-6), 7.82 (<italic>m</italic>, 1H, H-7), 8.68 (<italic>s</italic>, 1H, H-of benzylidene carbon), 6.14 (<italic>m</italic>, 1H, H-2<sup>\\</sup>), 1.85 (<italic>d</italic>, 3H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-3<sup>\\</sup>), 1.92 (<italic>s</italic>, 3H, H-4<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.24 (2C, C-1, C-3), 134.82 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.58 (2C, C-4, C-7), 134.39 (2C, C-5, C-6), 165.12 (1C, C- benzylidene), 130.49 (1C, C-1<sup>\\</sup>), 140.60 (1C, C-2<sup>\\</sup>), 10.51 (1C, C-3<sup>\\</sup>), 14.63 (1C, C-4<sup>\\</sup>). HREIMS <italic>m/z</italic>: 229.0989 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> 228.2510).</p></list-item><list-item><label>(4)</label><p>(E)-2-((3-Bromobenzylidene)amino)isoindoline-1,3-dione (H4): a white crystal product of 1.69 gram (Yield 83&#x0025;); MP: 151&#x2013;153&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;2970 (C&#x2013;H of ring), 1719 (C&#x3d;O), 1606 (C&#x3d;N), 1556 (C&#x3d;C), 1305 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.87 (<italic>m</italic>, 1H, H-4), 7.73 (<italic>m</italic>, 1H, H-5), 7.73 (<italic>m</italic>, 1H, H-6), 7.87 (<italic>m</italic>, 1H, H-7), 9.35 (<italic>s</italic>, 1H, H-of benzylidene carbon), 8.02 (<italic>s</italic>, 1H, H-2<sup>\\</sup>), 7.53 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-4<sup>\\</sup>), 7.27 (<italic>t</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6, 12&#x2009;Hz, H-5<sup>\\</sup>), 7.72 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-6<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.02 (2C, C-1, C-3), 134.46 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.92 (2C, C-4, C-7), 134.80 (2C, C-5, C6), 156.18 (1C, C- benzylidene), 135.79 (1C, C-1<sup>\\</sup>), 130.78 (1C, C-2<sup>\\</sup>), 123.06 (1C, C-3<sup>\\</sup>), 130.28 (1C, C-4<sup>\\</sup>), 130.25 (1C, C-5<sup>\\</sup>), 127.19 (1C, C-6<sup>\\</sup>). HREIMS <italic>m/z</italic>: 330.9901 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>15</sub>H<sub>9</sub>BrN<sub>2</sub>O<sub>2</sub> 329.1530).</p></list-item><list-item><label>(5)</label><p>(E)-2-((3-Bromo-4-hydroxybenzylidene)amino)isoindoline-1,3-dione (H5): a pale-yellow powder product of 1.92 gram (Yield 90&#x0025;); MP: 209&#x2013;211&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3328 (O&#x2013;H), 2930 (C&#x2013;H of ring), 1709 (C&#x3d;O), 1601 (C&#x3d;N), 1562 (C&#x3d;C), 1310 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, DMSO) ppm: 7.93 (<italic>m</italic>, 1H, H-4), 7.89 (<italic>m</italic>, 1H, H-5), 7.89 (<italic>m</italic>, 1H, H-6), 7.93 (<italic>m</italic>, 1H, H-7), 9.07 (<italic>s</italic>, 1H, H-of benzylidene carbon), 8.03 (<italic>d</italic>, 1H, H-2<sup>\\</sup>), 7.08 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-5<sup>\\</sup>) 7.73 (<italic>dd</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;Hz, H-6<sup>\\</sup>), 11.13 (s, 1H, -OH). <sup>13</sup>C-NMR (150&#x2009;MHz, DMSO) ppm: 164.97 (2C, C-1, C-3), 133.08 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.89 (2C, C-4, C-7), 135.36 (2C, C-5,C-6), 159.25 (1C, C- benzylidene), 126.35 (1C, C-1<sup>\\</sup>), 130.55 (1C, C-2<sup>\\</sup>), 110.46 (1C, C-3<sup>\\</sup>), 157.89 (1C, C-4<sup>\\</sup>), 117.14 (1C, C-5<sup>\\</sup>), 129.58 (1C, C-6<sup>\\</sup>). HREIMS <italic>m/z</italic>: 346.9845 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>15</sub>H<sub>9</sub>BrN<sub>2</sub>O<sub>3</sub> 345.1520).</p></list-item><list-item><label>(6)</label><p>(E)-2-((3-Bromo-4-fluorobenzylidene)amino)isoindoline-1,3-dione (H6): white powder product of 1.64 gram (Yield 77&#x0025;); MP: 177&#x2013;179&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3045 and 2935 (C&#x2013;H of ring), 1715 (C&#x3d;O), 1598 (C&#x3d;N), 1508 (C&#x3d;C), 1302 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.95 (<italic>m</italic>, 1H, H-4), 7.83 (<italic>m</italic>, 1H, H-5), 7.83 (<italic>m</italic>, 1H, H-6), 7.95 (<italic>m</italic>, 1H, H-7), 9.43 (<italic>s</italic>, 1H, H- of benzylidene carbon), 8.17 (<italic>dd</italic>, 1H, H-2<sup>\\</sup>), 7.23 (<italic>t</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6, 12&#x2009;Hz, H-5<sup>\\</sup>), 7.83 (<italic>dd</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;Hz, H-6<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 164.99 (2C, C-1, C-3), 133.17 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.92 (2C, C-4, C-7), 134.82 (2C, C-5, C-6), 154.99 (1C, C- benzylidene), 130.20 (1C, C-1<sup>\\</sup>), 131.44 (1C, C-2<sup>\\</sup>), 109.95 (1C, C-3<sup>\\</sup>), 160.15 (1C, C-4<sup>\\</sup>), 116.81 (1C, C-5<sup>\\</sup>), 129.26 (1C, C-6<sup>\\</sup>). HREIMS <italic>m/z</italic>: 348.9795 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>15</sub>H<sub>8</sub>BrFN<sub>2</sub>O<sub>2</sub> 347.1434).</p></list-item><list-item><label>(7)</label><p>(E)-2-((4-Hydroxy-3,5-dimethoxybenzylidene)amino)isoindoline-1,3-dione (H7): a dark yellow powder product of 1.38 gram (Yield 69&#x0025;); MP: 159&#x2013;161&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3317 (O&#x2013;H), 2994-2937 (C&#x2013;H of ring and of CH<sub>3</sub>), 1713 (C&#x3d;O), 1609 (C&#x3d;N), 1579 (C&#x3d;C), 1303 (C&#x2013;N), 1115 and 1085 (ether). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.85 (<italic>m</italic>, 1H, H-4), 7.71 (<italic>m</italic>, 1H, H-5), 7.71 (<italic>m</italic>,1H, H-6), 7.85 (<italic>m</italic>, 1H, H-7), 9.13 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.08 (<italic>s</italic>, 1H, H-2<sup>\\</sup>), 5.81 (<italic>s</italic>,1H, OH), <italic>7</italic>.08 (<italic>s</italic>, 1H, H-6<sup>\\</sup>), 3.91 (<italic>s</italic>, 6H, 2 X -OCH<sub>3</sub>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.20 (2C, C-1, C-3), 130.40 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.72 (2C, C-4, C-7), 134.58 (2C, C-5, C-6), 159.48 (1C, C- benzylidene), 124.82 (1C, C-1<sup>\\</sup>), 105.47 (2C, C-2<sup>\\</sup>, C-6<sup>\\</sup>), 147.26 (2C, C-3<sup>\\</sup>, C-5<sup>\\</sup>), 138.37 (1C, C-4<sup>\\</sup>), 56.54 (2C, 2 X -OCH<sub>3</sub>). HREIMS <italic>m/z</italic>: 327.0966 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>17</sub>H<sub>14</sub>N<sub>2</sub>O<sub>5</sub> 326.3080).</p></list-item><list-item><label>(8)</label><p>(E)-2-((3,5-Di-tert-butyl-2-hydroxybenzylidene)amino)isoindoline-1,3-dione (H8): a milky powder product of 1.89 gram (Yield 81&#x0025;); MP: 164-166&#x00B0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M8"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3319 (O&#x2013;H), 3033-2874 (C&#x2013;H of ring and of CH<sub>3</sub>), 1718 (C&#x3d;O), 1610 (C&#x3d;N), 1582 (C&#x3d;C), 1313 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.82 (<italic>m</italic>, 1H, H-4), 7.95 (<italic>m</italic>, 1H, H-5), 7.95 (<italic>m</italic>, 1H, H-6), 7.82 (<italic>m</italic>, 1H, H-7), 9.46 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.19 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-4<sup>\\</sup>), 7.76 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-6<sup>\\</sup>), 4.18 (s, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-2<sup>\\</sup> (OH)), 1.35 (<italic>s</italic>, 9H, <italic>t</italic>-butyl (8<sup>\</sup>)), 1.49 (<italic>s</italic>, 9H, <italic>t</italic>-butyl (7<sup>\\</sup>)). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 164.36 (2C, C-1, C-3), 128.42 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.89 (2C, C-4, C-7), 134.75 (2C, C-5, C-6), 156.71 (1C, C- benzylidene), 116.36 (1C, C-1<sup>\\</sup>), 123.50 (1C, C-6<sup>\\</sup>), 130.25 (1C, C-5<sup>\\</sup>), 127.21 (1C, C-4<sup>\\</sup>), 137.28 (1C, C-3<sup>\\</sup>), 162.31 (1C, C-2<sup>\\</sup>), 35.19 (1C, C-8<sup>\\</sup>), 34.21 (1C, C-7<sup>\\</sup>), 31.46 (3C, <italic>t</italic>-butyl C-7<sup>\\</sup>), 29.45 (3C, <italic>t</italic>-butyl C-8<sup>\\</sup>). HREIMS <italic>m/z</italic>: 379.2027 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>23</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub> 378.4720).</p></list-item><list-item><label>(9)</label><p>(E)-3-((4(((1,3-Dioxoisoindolin-2-yl)imino)methyl)phenyl) (methyl)amino) propanenitrile (H9): a yellow crystal product of 1.74 gram (Yield 85&#x0025;); MP: 155&#x2013;157&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M9"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3034 and 2907 (C&#x2013;H of ring and of CH<sub>3</sub>), 2252 (C&#x2261;N) 1709 (C&#x3d;O), 1610 (C&#x3d;N), 1589 (C&#x3d;C), 1306 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.69 (<italic>m</italic>, 1H, H-4), 7.82 (<italic>m</italic>, 1H, H-5), 7.82 (<italic>m</italic>, 1H, H-6), 7.69 (<italic>m</italic>, 1H, H-7), 9.05 (<italic>s</italic>, 1H, H- of benzylidene carbon), 6.64 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-2<sup>\\</sup>), 7.72 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-3<sup>\\</sup>), 7.72 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-5<sup>\\</sup>), 6.64 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-6<sup>\\</sup>), 3.07 (<italic>s</italic>, 3H, H-7<sup>\\</sup>), 3.73 (<italic>t</italic>, 2H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-8<sup>\\</sup>), 2.57 (<italic>t</italic>, 2H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-9<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.31 (2C, C-1, C-3), 130.50 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.57 (2C, C-4, C-7), 134.42 (2C, C-5, C-6), 159.93 (1C, C- benzylidene), 123.57 (1C, C-1<sup>\\</sup>), 122.50 (2C, C-2<sup>\\</sup>, C-6<sup>\\</sup>), 111.72 (2C, C-3<sup>\\</sup>, C-5<sup>\\</sup>), 150.18 (1C, C-4<sup>\\</sup>), 38.93 (1C, C-7<sup>\\</sup>), 48.56 (1C, C-8<sup>\\</sup>), 15.59 (1C, C-9<sup>\\</sup>), 118.01 (1C, C-10<sup>\\</sup>). HREIMS <italic>m/z</italic>: 333.1280 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> 332.3630).</p></list-item><list-item><label>(10)</label><p>(E)-2-((3-(<italic>p</italic>-Tolyloxy)benzylidene)amino)isoindoline-1,3-dione (H10): a white crystal product of 1.92 gram (Yield 88&#x0025;); MP: 103&#x2013;105&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M10"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;2918 (C&#x2013;H of ring and of CH<sub>3</sub>), 1716 (C&#x3d;O), 1601 (C&#x3d;N), 1571 (C&#x3d;C), 1302 (C&#x2013;N), 1105 and 1083 (ether). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.71 (<italic>m</italic>, 1H, H-4), 7.84 (<italic>m</italic>, 1H, H-5), 7.84 (<italic>m</italic>, 1H, H-6), 7.71 (<italic>m</italic>, 1H, H-7), 9.27 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.41 (<italic>s</italic>, 1H, H-2<sup>\\</sup>), 7.02 (<italic>m</italic>, 1H, H-4<sup>\\</sup>), 7.32 (<italic>t</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6, 12&#x2009;Hz, H-5<sup>\\</sup>), 7.53 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-6<sup>\\</sup>), 7.08 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-2<sup>\\\</sup>), 6.86 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-3<sup>\\\</sup>), 6.86 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-5<sup>\\\</sup>) 7.08 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-6<sup>\\\</sup>), 2.28 (<italic>s</italic>, 3H, H-7<sup>\\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.04 (2C, C-1, C-3), 130.41 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.81 (2C, C-4,C-7), 134.68 (2C, C-5, C-6), 158.03 (1C, C- benzylidene), 135.38 (1C, C-1<sup>\\</sup>), 117.82 (1C, C-2<sup>\\</sup>), 158.33 (1C, C-3<sup>\\</sup>), 122.87 (1C, C-4<sup>\\</sup>), 121.57 (1C, C-5<sup>\\</sup>), 133.38 (1C, C-6<sup>\\</sup>), 154.30 (1C, C-1<sup>\\\</sup>), 119.29 (2C, C-2<sup>\\\</sup>, C-6<sup>\\\</sup>), 130.05 (2C, C-3<sup />, C-5<sup>\\\</sup>), 130.31 (1C, C-4<sup>\\\</sup>), 20.75 (1C, C-7<sup>\\\</sup>). HREIMS <italic>m/z</italic>: 357.1158 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>22</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> 356.3810).</p></list-item><list-item><label>(11)</label><p>(E)-2-((2-Fluorobenzylidene)amino)isoindoline-1,3-dione (H11):</p></list-item><list-item><label>&#x2009;</label><p>a white crystal product of 0.65 gram (Yield 79&#x0025;); MP: 156&#x2013;158&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M11"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;2934 (C&#x2013;H of ring), 1717 (C&#x3d;O), 1612 (C&#x3d;N), 1510 (C&#x3d;C), 1313 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.81 (<italic>m</italic>, 1H, H-4), 7.95 (<italic>m</italic>, 1H, H-5), 7.95 (<italic>m</italic>, 1H, H-6), 7.81 (<italic>m</italic>, 1H, H-7), 9.70 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.26 (<italic>t</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6, 6&#x2009;Hz, H-3<sup>\\</sup>), 7.48 (<italic>m</italic>, 1H, H-4<sup>\\</sup>), 7.14 (<italic>t</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6, 6&#x2009;Hz, H-5<sup />), 8.22 (<italic>m</italic>, 1H, H-6<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 164.95 (2C, C-1, C-3), 130.29 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.87 (2C, C-4, C-7), 134.74 (2C, C-5, C-6), 151.85 (1C, C- benzylidene), 121.61 (1C, C-1<sup>\\</sup>), 161.45 (1C, C-2<sup>\\</sup>), 115.83 (1C, C-3<sup>\\</sup>), 127.28 (1C, C-4<sup>\\</sup>), 124.51 (1C, C-5<sup>\\</sup>), 133.31 (1C, C-6<sup>\\</sup>). HREIMS <italic>m/z</italic>: 269.0725 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>15</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>2</sub> 268.2474).</p></list-item><list-item><label>(12)</label><p>(E)-2-((3-Fluorobenzylidene)amino)isoindoline-1,3-dione (H12): a white crystal product of 0.58 gram (Yield 71&#x0025;); MP: 147&#x2013;149&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M12"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3035 (C&#x2013;H of ring), 1718 (C&#x3d;O), 1609 (C&#x3d;N), 1574 (C&#x3d;C), 1305 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.73 (<italic>m</italic>, 1H, H-4), 7.86 (<italic>m</italic>, 1H, H-5), 7.86 (<italic>m</italic>, 1H, H-6), 7.73 (<italic>m</italic>, 1H, H-7), 9.37 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.59 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;Hz, H-2<sup>\\</sup>), 7.11 (<italic>m</italic>, 1H, H-4<sup>\\</sup>), 7.35 (<italic>m</italic>, 1H, H-5<sup>\\</sup>), 7.54 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-6<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.01 (2C, C-1, C-3), 130.26 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.88 (2C, C-4, C-7), 134.77 (2C, C-5, C-6), 156.49 (1C, C- benzylidene), 136.01 (1C, C-1<sup>\\</sup>), 114.24 (1C, C-2<sup>\\</sup>), 162.20 (1C, C-3<sup>\\</sup>), 118.52 (1C, C-4<sup>\\</sup>), 130.32 (1C, C-5<sup>\\</sup>), 124.64 (1C, C-6<sup>\\</sup>). HREIMS <italic>m/z</italic>: 269.0714 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>15</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>2</sub> 268.2474).</p></list-item><list-item><label>(13)</label><p>(E)-2-((4-Fluorobenzylidene)amino)isoindoline-1,3-dione (H13): a milky crystal product of 0.6 gram (Yield 73&#x0025;); MP: 163&#x2013;165&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M13"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;3037 (C&#x2013;H of ring), 1716 (C&#x3d;O), 1608 (C&#x3d;N), 1507 (C&#x3d;C), 1308 (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.94 (<italic>m</italic>, 1H, H-4), 7.94 (<italic>m</italic>, 1H, H-5), 7.94 (<italic>m</italic>, 1H, H-6), 7.94 (<italic>m</italic>, 1H, H-7), 9.40 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.80 (<italic>m</italic>,1H, H-2<sup>\\</sup>), 7.17 (<italic>m</italic>, 1H, H-3<sup>\\</sup>), 7.17 (<italic>m</italic>, 1H, H-5<sup>\\</sup>), 7.80 (<italic>m</italic>, 1H, H-6<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.74 (2C, C-1, C-3), 130.50 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.81 (2C, C-4, C-7), 134.69 (2C, C-5, C-6), 157.15 (1C, C- benzylidene), 130.31 (1C, C-1<sup>\\</sup>), 130.44 (2C, C-2<sup>\\</sup>, C-6<sup>\\</sup>), 115.95 (2C, C-3<sup>\\</sup>, C-5<sup>\\</sup>), 164.07 (1C, C-4<sup>\\</sup>). HREIMS <italic>m/z</italic>: 269.0716 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>15</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>2</sub> 268.2474).</p></list-item><list-item><label>(14)</label><p>(E)-2-((3,5-Di-<italic>tert</italic>-butyl-2-methoxybenzylidene)amino)isoindole 1,3-dione (H14): a milky crystal product of 2.27 gram (Yield 94&#x0025;); MP: 135&#x2013;137&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M14"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;2952-2868 (C&#x2013;H of ring, <italic>t</italic>-Bu and CH<sub>3</sub>), 1720 (C&#x3d;O), 1608 (C&#x3d;N), 1587 (C&#x3d;C), 1307 (C&#x2013;N), 1116 and 1083 (ether). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.94 (<italic>m</italic>, 1H, H-4), 7.80 (<italic>m</italic>, 1H, H-5), 7.80 (<italic>m</italic>, 1H, H-6), 7.94 (<italic>m</italic>, 1H, H-7), 9.52 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.52 (<italic>d</italic>, 1H, H-4<sup>\\</sup>), 8.01 (<italic>d</italic>, 1H, H-6<sup>\\</sup>), 1.37 (<italic>s</italic>, 9H, <italic>t</italic>-butyl (C-8<sup>\\</sup>)), 1.45 (<italic>s</italic>, 9H, <italic>t</italic>-butyl (C-7<sup>\\</sup>)), 3.93 (<italic>s</italic>, 3H, -OCH<sub>3</sub>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.11 (2C, C-1, C-3), 130.50 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 126.28 (2C, C-4, C-7), 134.54 (2C, C-5, C-6), 158.59 (1C, C- benzylidene), 122.36 (1C, C-1<sup>\\</sup>), 158.83 (1C, C-2<sup>\\</sup>), 142.26 (1C, C-3<sup>\\</sup>), 128.27 (1C, C-4<sup>\\</sup>), 146.23 (1C, C-5<sup>\\</sup>), 123.69 (1C, C-6<sup>\\</sup>), 35.25 (1C, C-7<sup>\\</sup>), 34.75 (1C, C-8<sup>\\</sup>), 64.66 (1C, -OCH), 31.44 (3C, <italic>t</italic>-butyl (C-7<sup>\\</sup>)), 30.92 (3C, <italic>t</italic>-butyl (C-8<sup>\\</sup>)). HREIMS <italic>m/z</italic>: 393.2089 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub> 392.4990).</p></list-item><list-item><label>(15)</label><p>(E)-2-((4-Butoxybenzylidene)amino)isoindoline-1,3-dione (H15): a white powder product of 0.91 gram (Yield 89&#x0025;); MP: 101&#x2013;104&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M15"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;2953 and 2873 (C&#x2013;H of ring and CH<sub>3</sub>), 1715 (C&#x3d;O), 1641 (C&#x3d;N), 1589 (C&#x3d;C), 1313 (C &#x2013; N), 1121 and 1083 (ether). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.83 (<italic>m</italic>, 1H, H-4), 7.69 (<italic>m</italic>, 1H, H-5), 7.69 (<italic>m</italic>, 1H, H-6), 7.83 (<italic>m</italic>, 1H, H-7), 9.16 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.75 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-2<sup>\\</sup>), 6.87 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-3<sup>\\</sup>), 6.87 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-5<sup>\\</sup>), 7.75 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-6<sup>\\</sup>), 3.95 (<italic>t</italic>, 2H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6, 6&#x2009;Hz, H-7<sup>\\</sup>), 1.72 (<italic>m</italic>, 2H, H-8<sup>\\</sup>), 1.43 (<italic>m</italic>, 2H, H-9<sup>\\</sup>), 0.92 (<italic>t</italic>, 3H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6, 12&#x2009;Hz, H-10<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.22 (2C, C-1, C-3), 130.45 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.65 (2C, C-4, C-7), 134.49 (2C, C-5, C-6), 159.21 (1C, C- benzylidene), 125.97 (1C, C-1<sup>\\</sup>), 130.26 (2C, C-2<sup>\\</sup>, C-6<sup>\\</sup>), 114.73 (2C, C-3<sup>\\</sup>, C-5<sup>\\</sup>), 162.24 (1C, C-4<sup>\\</sup>), 67.91 (1C, C-7<sup>\\</sup>), 31.20 (1C, C-8<sup>\\</sup>), 19.22 (1C, C-9<sup>\\</sup>), 13.84 (1C, C-10<sup>\\</sup>). HREIMS <italic>m/z</italic>: 323.1389 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> 322.3640).</p></list-item><list-item><label>(16)</label><p>(E)-2-((4-Isopropylbenzylidene)amino)isoindoline-1,3-dione (H16): a milky powder product of 0.38 gram (Yield 43&#x0025;); MP: 99&#x2013;101&#xb0;C. IR, cm<sup>&#x2212;1</sup>: <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M16"><mml:mi>v</mml:mi></mml:math></inline-formula>&#x2009;&#x3d;&#x2009;2960-2876 (C&#x2013;H of ring and CH<sub>3</sub>), 1717 (C&#x3d;O), 1609 (C&#x3d;N), 1598 (C&#x3d;C), 1302. (C&#x2013;N). <sup>1</sup>H-NMR (600&#x2009;MHz, CDCl<sub>3</sub>) ppm: 7.84 (<italic>m</italic>, 1H, H-4), 7.70 (<italic>m</italic>, 1H, H-5), 7.70 (<italic>m</italic>, 1H, H-6), 7.84 (<italic>m</italic>, 1H, H-7), 9.25 (<italic>s</italic>, 1H, H- of benzylidene carbon), 7.74 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-2<sup>\\</sup>), 7.24 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-3<sup>\\</sup>), 7.24 (<italic>d</italic>, 1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-5<sup>\\</sup>), 7.74 (<italic>d</italic>,1H, <italic>J</italic>&#x2009;&#x3d;&#x2009;12&#x2009;Hz, H-6<sup>\\</sup>), 2.89 (<italic>m</italic>, 1H, H-7<sup>\\</sup>), 1.20 (<italic>d</italic>, 3H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-8<sup>\\</sup>), 1.21 (<italic>d</italic>, 2H, <italic>J</italic>&#x2009;&#x3d;&#x2009;6&#x2009;Hz, H-9<sup>\\</sup>). <sup>13</sup>C-NMR (150&#x2009;MHz, CDCl<sub>3</sub>) ppm: 165.15 (2C, C-1, C-3), 131.26 (2C, C-1<sup>\</sup>, C-3<sup>\</sup>), 123.71 (2C, C-4, C-7), 134.55 (2C, C-5, C-6), 159.12 (1C, C- benzylidene), 130.42 (1C, C-1<sup>\\</sup>), 128.59 (2C, C-2<sup>\\</sup>, C-6<sup>\\</sup>), 126.91 (2C, C-3<sup>\\</sup>, C-5<sup>\\</sup>), 153.17 (1C, C-4<sup>\\</sup>), 34.26 (1C, C-7<sup>\\</sup>), 23.76 (2C, C-8<sup>\\</sup>, C-9<sup>\\</sup>). HREIMS <italic>m/z</italic>: 293.1277 [M&#x2009;&#x2b;&#x2009;H<sup>&#x2b;</sup>] (Calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> 292.3380).</p></list-item></list></p></sec><sec id="sec5.2"><title>5.2. Biological Activities</title><sec id="sec5.2.1"><title>5.2.1. Antioxidant DPPH Free Radical Scavenging Assay</title><p>&#x2009;The DPPH radical scavenging assay was done according to the procedure followed in the literature [<xref ref-type="bibr" rid="B34">34</xref>]. DPPH solution (0.1&#x2009;mM DPPH solution in methanol) was added (1.0&#x2009;ml) to a range of various samples&#x2019; concentrations (5, 10, 50, 100, 150, 300, and 600&#x2009;<italic>&#xb5;</italic>M), while methanol served as negative control and BHT as a positive control. The mixture was then incubated in the dark for 60 minutes at room temperature. Absorbance at 517&#x2009;nm for each sample was then measured. The free radical scavenging activity of the compounds was calculated as a percentage of radical inhibition using the following equation:<disp-formula><mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M17"><mml:mtable><mml:mlabeledtr id="EEq1"><mml:mtd><mml:mtext>(1)</mml:mtext></mml:mtd><mml:mtd><mml:mtext>percentage&#x2009;of&#x2009;inhibition</mml:mtext><mml:mo>&#x3d;</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="(" close=")" separators="&#x7C;"><mml:mrow><mml:mtext>Ac</mml:mtext><mml:mo>&#x2212;</mml:mo><mml:mtext>As</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mtext>Ac</mml:mtext></mml:mrow></mml:mfrac><mml:mo>&#xd7;</mml:mo><mml:mn>100</mml:mn><mml:mo>,</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math></disp-formula>where As is the absorbance of the compounds/positive control and Ac is the absorbance of the negative control. Each assay was carried out in triplicate. The concentration required to achieve 50&#x0025; inhibition (IC<sub>50</sub>) of the DPPH radical was determined by plotting each compound&#x2019;s percentage result and exact concentration.</p></sec><sec id="sec5.2.2"><title>5.2.2. Cell Culture</title><p>Human <italic>in vitro</italic> cell lines of colon cancer HT-29 (colon adenocarcinoma), breast cancer MCF-7 (breast adenocarcinoma), normal colon CCD841-Con, and normal breast cells MCF-10A were all obtained from the American Type Culture Collection (ATCC, Manassas, USA). Cells were cultured in RPMI-1640 media (Sigma Aldrich, USA) supplemented with 10&#x0025; fetal bovine serum (Gibco, USA) and 1&#x0025; Pen-Strip antibiotic (10,000 units penicillin-10&#x2009;mg streptomycin/mL, Sigma Aldrich, USA) in a 37&#xb0;C, 5&#x0025; CO<sub>2</sub> incubator (Thermo Fisher Scientific, USA).</p></sec><sec id="sec5.2.3"><title>5.2.3. MTT Cytotoxicity Assay</title><p>Cell viability assay 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was conducted based on a previously modified protocol [<xref ref-type="bibr" rid="B48">48</xref>]. Briefly, the cells were plated into 96-well plates at the density of 5000 cells/well in the final volume of 100&#x2009;<italic>&#x3bc;</italic>L culture medium per well. On the following day, the cells were treated with the respective samples&#x2019; treatments (800, 400, 200, 100, 50, and 25&#x2009;<italic>&#xb5;</italic>M), while the standard cytotoxic drugs 5-fluorouracil (5-FU) and tamoxifen (Tmx) served as positive controls. Cells were incubated at 37&#xb0;C with 5&#x0025; CO<sub>2</sub> for 24 hours. Cells without treatment were used as a negative control. At the end of the incubation period, 10&#x2009;<italic>&#x3bc;</italic>L of MTT reagent (5&#x2009;mg/mL) was added to each well and incubated again for 4 hours at 37&#xb0;C with 5&#x0025; CO<sub>2</sub>, then the supernatant was removed and 100&#x2009;<italic>&#x3bc;</italic>L of dimethylsulphoxide (DMSO) was added to each well, and the absorbance was determined at 570&#x2009;nm using microplate reader (Infinite-M200Pro-TECAN). The experiment was carried out in triplicate, and cellular viability was calculated according to <disp-formula><mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M18"><mml:mtable><mml:mlabeledtr id="EEq2"><mml:mtd><mml:mtext>(2)</mml:mtext></mml:mtd><mml:mtd><mml:mtext>cell&#x2009;viability</mml:mtext><mml:mtext>&#x2009;</mml:mtext><mml:mfenced open="(" close=")" separators="&#x7C;"><mml:mrow><mml:mo>&#x0025;</mml:mo></mml:mrow></mml:mfenced><mml:mo>&#x3d;</mml:mo><mml:mfrac><mml:mrow><mml:mtext>sample&#x2009;absorbance</mml:mtext></mml:mrow><mml:mrow><mml:mtext>control&#x2009;absorbance</mml:mtext></mml:mrow></mml:mfrac><mml:mo>&#xd7;</mml:mo><mml:mn>100.</mml:mn></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math></disp-formula></p></sec><sec id="sec5.2.4"><title>5.2.4. Selectivity Index (SI)</title><p>The degree of selectivity of chemicals to each cancer cell line is explored as SI ratio as per previous reports [<xref ref-type="bibr" rid="B49">49</xref>], according to the following equation:<disp-formula><mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M19"><mml:mtable><mml:mlabeledtr id="EEq3"><mml:mtd><mml:mtext>(3)</mml:mtext></mml:mtd><mml:mtd><mml:mtext>SI</mml:mtext><mml:mo>&#x3d;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mtext>IC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x2009;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x2009;sample&#x2009;on&#x2009;normal&#x2009;cell&#x2009;lines</mml:mtext></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>IC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x2009;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x2009;sample&#x2009;on&#x2009;cancer&#x2009;cell&#x2009;line</mml:mtext></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math></disp-formula></p></sec></sec></sec><sec id="sec6"><title>6. Conclusions</title><p>A series of hybridized imines were synthesized combining the active phthalimide pharmacophore and various phenolic aldehydes with various functionalities. The facile one-step synthesis method substituted the conventional chemical two-step route. Among these compounds, H7 presented superior antioxidant activity against DPPH free radical which may reflect the phenolic group-bearing structure. As such, H7 and H6 were colon cancer cytotoxic active agents with concurrent acceptable safety, surpassing the starting material N-aminophthalimide. Breast cancer was also screened and was inhibited by compounds H6 and H14. These findings suggest that hybridized imines and especially the halogenated H6 structure have successfully amplified anticancer activities, which create a promising window for a novel therapeutic strategy.</p></sec></body><back><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are available from the corresponding author upon request.</p></sec><sec><title>Disclosure</title><p>The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec><title>Authors&#x2019; Contributions</title><p>Hayman Sardar Abdulrahman was responsible for data curation; Hayman Sardar Abdulrahman, Lina A. Al-Ani, and Mohd Hafiz Ahmad performed formal analysis; Wageeh A. Yehye was responsible for funding acquisition; Hayman Sardar Abdulrahman and Najihah M. Hashim investigated the study; Hayman Sardar Abdulrahman and Mohamed Hassan Mohammed were responsible for the methodology of the study; Mohd Hafiz Ahmad was involved in project administration; Mohamed Hassan Mohammed and Wageeh A. Yehye supervised the study; Hayman Sardar Abdulrahman and Mohamed Hassan Mohammed wrote the original draft; Lina A. Al-Ani, Wageeh A. Yehye, and Hayman Sardar Abdulrahman reviewed and edited the manuscript.</p></sec><ack><title>Acknowledgments</title><p>The authors would like to thank the University of Malaya, Malaysia, and Hawler Medical University, Erbil, Kurdistan Region, Iraq, for their cordial support in completing this work. This work was financially supported by the grant RP044C-17AET (UMRG) by the University of Malaya, Malaysia.</p></ack><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material id="supp-1" xlink:href="http://downloads.hindawi.com/journals/jchem/2020/3928204.f1.pdf" mimetype="application/pdf"><label>Supplementary Materials</label><caption><p>The following are available online at <ext-link ext-link-type="uri" xlink:href="http://www.mdpi.com/xxx/s1">http://www.mdpi.com/xxx/s1</ext-link>. Figures 1.1&#x2013;1.16: the full FT-IR spectra of the synthesized imines. Figures 2.1&#x2013;2.16: the full <sup>1</sup>H-NMR spectra of the synthesized imines. Figures 3.1&#x2013;3.16: the full <sup>13</sup>C-NMR spectra of the synthesized imines. Figure 4.1: DPPH free radical inhibition of the synthesized imines. Figure 5.1: colon cancer HT-29 cell line viability upon treatment with the synthesized imines. Figure 6.1: breast cancer MCF-7 cell line viability upon treatment with the synthesized imines.</p></caption></supplementary-material></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohs</surname><given-names>R. C.</given-names></name><name><surname>Greig</surname><given-names>N. H.</given-names></name></person-group><article-title>Drug discovery and development: role of basic biological research</article-title><source><italic>Alzheimer&#x2019;s &#x26; Dementia: Translational Research &#x26; Clinical Interventions</italic></source><year>2017</year><volume>3</volume><issue>126</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2017.10.005</pub-id><pub-id pub-id-type="other">2-s2.0-85037068056</pub-id></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alaklabi</surname><given-names>A.</given-names></name><name><surname>Arif</surname><given-names>I. A.</given-names></name><name><surname>Ahamed</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>R. S.</given-names></name><name><surname>Idhayadhulla</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of antioxidant and anticancer activities of chemical constituents of the saururus chinensis root extracts</article-title><source><italic>Saudi Journal of Biological Sciences</italic></source><year>2018</year><volume>25</volume><issue>127</issue><fpage>1387</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1016/j.sjbs.2016.12.021</pub-id><pub-id pub-id-type="other">2-s2.0-85009965894</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haq</surname><given-names>S. H.</given-names></name><name><surname>Al-Ruwaished</surname><given-names>G.</given-names></name><name><surname>Al-Mutlaq</surname><given-names>M. A.</given-names></name><etal /></person-group><article-title>Antioxidant, anticancer activity and phytochemical analysis of green algae, chaetomorpha collected from the Arabian Gulf</article-title><source><italic>Scientific Reports</italic></source><year>2019</year><volume>9</volume><issue>128</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-55309-1</pub-id></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>RA Abdellatif</surname><given-names>K.</given-names></name><name><surname>A Abdelgawad</surname><given-names>M.</given-names></name><name><surname>AH Elshemy</surname><given-names>H.</given-names></name><name><surname>M Kahk</surname><given-names>N.</given-names></name><name><surname>M El Amir</surname><given-names>D.</given-names></name></person-group><article-title>Design, synthesis, antioxidant and anticancer activity of new coumarin derivatives linked with thiazole, isoxazole or pyrazole moiety</article-title><source><italic>Letters in Drug Design &#x26; Discovery</italic></source><year>2017</year><volume>14</volume><issue>129</issue><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.2174/1570180813666161026153743</pub-id><pub-id pub-id-type="other">2-s2.0-85026752673</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>H.</given-names></name><name><surname>Khatami</surname><given-names>M.</given-names></name></person-group><article-title>Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs</article-title><source><italic>Clinical and Translational Medicine</italic></source><year>2018</year><volume>7</volume><issue>2</issue><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s40169-018-0185-6</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>F.</given-names></name></person-group><article-title>Use of antioxidants in the prevention and treatment of disease</article-title><source><italic>Journal of the International Federation of Clinical Chemistry</italic></source><year>1998</year><volume>10</volume><issue>1</issue><fpage>21</fpage><lpage>23</lpage></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serafini</surname><given-names>M.</given-names></name></person-group><article-title>The role of antioxidants in disease prevention</article-title><source><italic>Medicine</italic></source><year>2006</year><volume>34</volume><issue>144</issue><fpage>533</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1053/j.mpmed.2006.09.007</pub-id><pub-id pub-id-type="other">2-s2.0-33845257823</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada-Junior</surname><given-names>C. Y.</given-names></name><name><surname>Monteiro</surname><given-names>G. C.</given-names></name><name><surname>Aguiar</surname><given-names>A. C. C.</given-names></name><etal /></person-group><article-title>Phthalimide derivatives with bioactivity against plasmodium falciparum: synthesis, evaluation, and computational studies involving bc 1 cytochrome inhibition</article-title><source><italic>ACS Omega</italic></source><year>2018</year><volume>3</volume><issue>130</issue><fpage>9424</fpage><lpage>9430</lpage><pub-id pub-id-type="doi">10.1021/acsomega.8b01062</pub-id><pub-id pub-id-type="other">2-s2.0-85051998808</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva J&#xfa;nior</surname><given-names>J. G.</given-names></name><name><surname>Holanda</surname><given-names>V. N.</given-names></name><name><surname>Rodrigues</surname><given-names>D. S.</given-names></name><etal /></person-group><article-title>Therapeutic potential of phthalimide derivatives: a review</article-title><source><italic>Biomedical Science &#x26; Research</italic></source><year>2019</year><volume>3</volume><issue>no. 4</issue><pub-id pub-id-type="doi">10.34297/ajbsr.2019.03.000699</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamie</surname><given-names>P. F.</given-names></name><name><surname>Philoppes</surname><given-names>J. N.</given-names></name><name><surname>El-Gendy</surname><given-names>A. O.</given-names></name><name><surname>Rarova</surname><given-names>L.</given-names></name><name><surname>Gruz</surname><given-names>J.</given-names></name></person-group><article-title>Design, synthesis and evaluation of novel phthalimide derivatives as in vitro anti-microbial, anti-oxidant and anti-inflammatory agents</article-title><source><italic>Molecules (Basel, Switzerland)</italic></source><year>2015</year><volume>20</volume><issue>132</issue><fpage>16620</fpage><lpage>16642</lpage><pub-id pub-id-type="doi">10.3390/molecules200916620</pub-id><pub-id pub-id-type="other">2-s2.0-84947968773</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>H. E. A.</given-names></name><name><surname>Abdel-Salam</surname><given-names>H. A.</given-names></name><name><surname>Shaker</surname><given-names>M. A.</given-names></name></person-group><article-title>Synthesis, characterization, molecular modeling, and potential antimicrobial and anticancer activities of novel 2-aminoisoindoline-1,3-dione derivatives</article-title><source><italic>Bioorganic Chemistry</italic></source><year>2016</year><volume>66</volume><issue>133</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2016.03.003</pub-id><pub-id pub-id-type="other">2-s2.0-84961635349</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kushwaha</surname><given-names>N.</given-names></name><name><surname>Kaushik</surname><given-names>D.</given-names></name></person-group><article-title>Recent advances and future prospects of phthalimide derivatives</article-title><source><italic>Journal of Applied Pharmaceutical Science</italic></source><year>2016</year><volume>6</volume><issue>135</issue><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.7324/japs.2016.60330</pub-id><pub-id pub-id-type="other">2-s2.0-84962780955</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asif</surname><given-names>M.</given-names></name></person-group><article-title>A review on biological and chemical potential of phthalimide and maleimide derivatives</article-title><source><italic>Acta Scientific Pharmaceutical Sciences</italic></source><year>2019</year><volume>3</volume><issue>227</issue><fpage>51</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.31080/asps.2019.03.0418</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayab</surname><given-names>P. S.</given-names></name><name><surname>Ansari</surname><given-names>I. A.</given-names></name><name><surname>Shahid</surname><given-names>M.</given-names></name></person-group><article-title>New phthalimide-appended schiff bases: studies of DNA binding, molecular docking and antioxidant activities</article-title><source><italic>Luminescence</italic></source><year>2017</year><volume>32</volume><issue>138</issue><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1002/bio.3259</pub-id><pub-id pub-id-type="other">2-s2.0-85010220029</pub-id></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajal</surname><given-names>A.</given-names></name><name><surname>Bala</surname><given-names>S.</given-names></name><name><surname>Kamboj</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Saini</surname><given-names>V.</given-names></name></person-group><article-title>Schiff bases: a versatile pharmacophore</article-title><source><italic>Journal of Catalysts</italic></source><year>2013</year><volume>2013</volume><issue>214</issue><pub-id pub-id-type="doi">10.1155/2013/893512</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>M. A.</given-names></name><name><surname>Al-Omar</surname><given-names>M. A.</given-names></name></person-group><article-title>Synthesis, characterization and in vivo anticonvulsant and neurotoxicity screening of schiff bases of phthalimide</article-title><source><italic>Acta Poloniae Pharmaceutica</italic></source><year>2011</year><volume>68</volume><issue>218</issue><fpage>375</fpage><lpage>380</lpage></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>G. K.</given-names></name><name><surname>Priya</surname><given-names>A.</given-names></name><name><surname>Priya</surname><given-names>S.</given-names></name><name><surname>Narayan</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and biological activity of some schiff&#x2019;s bases from phthalimides</article-title><source><italic>Universal Journal of Chemistry</italic></source><year>2017</year><volume>5</volume><issue>140</issue><fpage>36</fpage><lpage>42</lpage></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>K.-W.</given-names></name><name><surname>Lin</surname><given-names>Z.-C.</given-names></name><name><surname>Chen</surname><given-names>Y.-L.</given-names></name><name><surname>Tzeng</surname><given-names>C.-C.</given-names></name><name><surname>Fang</surname><given-names>J.-Y.</given-names></name><name><surname>Tseng</surname><given-names>C.-H.</given-names></name></person-group><article-title>Synthesis and biological evaluation of thalidomide derivatives as potential anti-psoriasis agents</article-title><source><italic>International Journal of Molecular Sciences</italic></source><year>2018</year><volume>19</volume><issue>8</issue><fpage>3061</fpage><pub-id pub-id-type="doi">10.3390/ijms19103061</pub-id><pub-id pub-id-type="other">2-s2.0-85054772944</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>E.</given-names></name><name><surname>Hijji</surname><given-names>Y. M.</given-names></name></person-group><article-title>A novel green synthesis of thalidomide and analogs</article-title><source><italic>Journal of Chemistry</italic></source><year>2017</year><volume>2017</volume><issue>9</issue><pub-id pub-id-type="doi">10.1155/2017/6436185</pub-id><pub-id pub-id-type="other">2-s2.0-85029367412</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munawar</surname><given-names>K. S.</given-names></name><name><surname>Haroon</surname><given-names>S. M.</given-names></name><name><surname>Haroon</surname><given-names>S. M.</given-names></name><name><surname>Hussain</surname><given-names>S. A.</given-names></name><name><surname>Raza</surname><given-names>H.</given-names></name></person-group><article-title>Schiff bases: multipurpose pharmacophores with extensive biological applications</article-title><source><italic>Journal of Basic &#x26; Applied Sciences</italic></source><year>2018</year><volume>14</volume><issue>141</issue><fpage>217</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.6000/1927-5129.2018.14.34</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelaal</surname><given-names>M. M.</given-names></name><name><surname>Mohamed</surname><given-names>S.</given-names></name><name><surname>Barakat</surname><given-names>Y.</given-names></name><name><surname>Derbala</surname><given-names>H. A.</given-names></name><name><surname>Hassan</surname><given-names>H. H.</given-names></name><name><surname>Al Zoubi</surname><given-names>W.</given-names></name></person-group><article-title>N-aminophthalimide as a synthon for heterocyclic schiff bases: efficient utilization as corrosion inhibitors of mild steel in 0.5 mol. L-1 H<sub>2</sub>SO<sub>4</sub> solution</article-title><source><italic>Egyptian Journal of Chemistry</italic></source><year>2018</year><volume>61</volume><issue>145</issue><fpage>539</fpage><lpage>558</lpage></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillis</surname><given-names>E. P.</given-names></name><name><surname>Eastman</surname><given-names>K. J.</given-names></name><name><surname>Hill</surname><given-names>M. D.</given-names></name><name><surname>Donnelly</surname><given-names>D. J.</given-names></name><name><surname>Meanwell</surname><given-names>N. A.</given-names></name></person-group><article-title>Applications of fluorine in medicinal chemistry</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>2015</year><volume>58</volume><issue>119</issue><fpage>8315</fpage><lpage>8359</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00258</pub-id><pub-id pub-id-type="other">2-s2.0-84942638403</pub-id></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>D. M.</given-names></name><name><surname>Valent&#xe3;o</surname><given-names>P.</given-names></name><name><surname>Pereira</surname><given-names>J. A.</given-names></name><name><surname>Andrade</surname><given-names>P. B.</given-names></name></person-group><article-title>Phenolics: from chemistry to biology</article-title><source><italic>Molecular Diversity Preservation International</italic></source><year>2009</year><volume>14</volume><issue>16</issue><fpage>2202</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.3390/molecules14062202</pub-id><pub-id pub-id-type="other">2-s2.0-67649988340</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cos</surname><given-names>P.</given-names></name><name><surname>Vlietinck</surname><given-names>A. J.</given-names></name><name><surname>Berghe</surname><given-names>D. V.</given-names></name><name><surname>Maes</surname><given-names>L.</given-names></name></person-group><article-title>Anti-infective potential of natural products: how to develop a stronger in vitro &#x201c;proof-of-concept&#x201d;</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2006</year><volume>106</volume><issue>12</issue><fpage>290</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2006.04.003</pub-id><pub-id pub-id-type="other">2-s2.0-33745435902</pub-id></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deore</surname><given-names>A. B.</given-names></name><name><surname>Dhumane</surname><given-names>J. R.</given-names></name><name><surname>Wagh</surname><given-names>R.</given-names></name><name><surname>Sonawane</surname><given-names>R.</given-names></name></person-group><article-title>The stages of drug discovery and development process</article-title><source><italic>Asian Journal of Pharmaceutical Research and Development</italic></source><year>2019</year><volume>7</volume><issue>16</issue><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.22270/ajprd.v7i6.616</pub-id></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koczurkiewicz</surname><given-names>P.</given-names></name><name><surname>Kla&#x15b;</surname><given-names>K.</given-names></name><name><surname>Grabowska</surname><given-names>K.</given-names></name><etal /></person-group><article-title>Saponins as chemosensitizing substances that improve effectiveness and selectivity of anticancer drug&#x2014;minireview of in vitro studies</article-title><source><italic>Phytotherapy Research</italic></source><year>2019</year><volume>33</volume><issue>17</issue><fpage>2141</fpage><lpage>2151</lpage><pub-id pub-id-type="doi">10.1002/ptr.6371</pub-id><pub-id pub-id-type="other">2-s2.0-85068791495</pub-id></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xavier</surname><given-names>A.</given-names></name><name><surname>Srividhya</surname><given-names>N.</given-names></name></person-group><article-title>Synthesis and study of schiff base ligands</article-title><source><italic>Journal of Applied Chemistry</italic></source><year>2014</year><volume>7</volume><issue>205</issue><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.9790/5736-071110615</pub-id></element-citation></ref><ref id="B28" content-type="book"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Riss</surname><given-names>T. L.</given-names></name><name><surname>Moravec</surname><given-names>R. A.</given-names></name><name><surname>Niles</surname><given-names>A. L.</given-names></name><etal /></person-group><source><italic>Cell Viability Assays, Assay Guidance Manual [Internet]</italic></source><year>2016</year><publisher-loc>Bethesda, MD, USA</publisher-loc><publisher-name>Eli Lilly &#x26; Company and the National Center for Advancing Translational Sciences</publisher-name></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liew</surname><given-names>S. K.</given-names></name><name><surname>Malagobadan</surname><given-names>S.</given-names></name><name><surname>Arshad</surname><given-names>N. M.</given-names></name><name><surname>Nagoor</surname><given-names>N. H.</given-names></name></person-group><article-title>A review of the structure-activity relationship of natural and synthetic antimetastatic compounds</article-title><source><italic>Biomolecules</italic></source><year>2020</year><volume>10</volume><issue>1</issue><fpage>138</fpage><pub-id pub-id-type="doi">10.3390/biom10010138</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>P.</given-names></name><name><surname>Westwell</surname><given-names>A. D.</given-names></name></person-group><article-title>The role of fluorine in medicinal chemistry</article-title><source><italic>Journal of Enzyme Inhibition and Medicinal Chemistry</italic></source><year>2007</year><volume>22</volume><issue>21</issue><fpage>527</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1080/14756360701425014</pub-id><pub-id pub-id-type="other">2-s2.0-35348938545</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antolovich</surname><given-names>M.</given-names></name><name><surname>Prenzler</surname><given-names>P. D.</given-names></name><name><surname>Patsalides</surname><given-names>E.</given-names></name><name><surname>McDonald</surname><given-names>S.</given-names></name><name><surname>Robards</surname><given-names>K.</given-names></name></person-group><article-title>Methods for testing antioxidant activity</article-title><source><italic>Analyst</italic></source><year>2002</year><volume>127</volume><issue>121</issue><fpage>183</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1039/b009171p</pub-id><pub-id pub-id-type="other">2-s2.0-0036141823</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apak</surname><given-names>R. A.</given-names></name><name><surname>O&#x308;zyu&#x308;rek</surname><given-names>M.</given-names></name><name><surname>Gu&#x308;c&#x327;lu&#x308;</surname><given-names>K.</given-names></name><name><surname>C&#x327;apanog&#x306;lu</surname><given-names>E.</given-names></name></person-group><article-title>Antioxidant activity/capacity measurement. 1. classification, physicochemical principles, mechanisms, and electron transfer (ET)-based assays</article-title><source><italic>Journal of Agricultural and Food Chemistry</italic></source><year>2016</year><volume>64</volume><issue>122</issue><fpage>997</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.5b04739</pub-id><pub-id pub-id-type="other">2-s2.0-84958243380</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amorati</surname><given-names>R.</given-names></name><name><surname>Valgimigli</surname><given-names>L.</given-names></name></person-group><article-title>Advantages and limitations of common testing methods for antioxidants</article-title><source><italic>Free Radical Research</italic></source><year>2015</year><volume>49</volume><issue>123</issue><fpage>633</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.3109/10715762.2014.996146</pub-id><pub-id pub-id-type="other">2-s2.0-84925583553</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yehye</surname><given-names>W.</given-names></name><name><surname>Abdul Rahman</surname><given-names>N.</given-names></name><name><surname>Saad</surname><given-names>O.</given-names></name><etal /></person-group><article-title>Rational design and synthesis of new, high efficiency, multipotent schiff base-1, 2, 4-triazole antioxidants bearing butylated hydroxytoluene moieties</article-title><source><italic>Molecules</italic></source><year>2016</year><volume>21</volume><issue>225</issue><fpage>847</fpage><pub-id pub-id-type="doi">10.3390/molecules21070847</pub-id><pub-id pub-id-type="other">2-s2.0-84979257989</pub-id></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perveen</surname><given-names>S.</given-names></name><name><surname>Orfali</surname><given-names>R.</given-names></name></person-group><article-title>L-proline-catalyzed synthesis of phthalimide derivatives and evaluation of their antioxidant, anti-inflammatory, and lipoxygenase inhibition activities</article-title><source><italic>Journal of Chemistry</italic></source><year>2018</year><volume>2018</volume><issue>15</issue><pub-id pub-id-type="doi">10.1155/2018/5198325</pub-id><pub-id pub-id-type="other">2-s2.0-85051586730</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lartigue</surname><given-names>J.</given-names></name></person-group><article-title>Tumor heterogeneity: a central foe in the war on cancer</article-title><source><italic>Journal of Community and Supportive Oncology</italic></source><year>2018</year><volume>16</volume><issue>13</issue><fpage>E167</fpage><lpage>E174</lpage><pub-id pub-id-type="doi">10.12788/jcso.0398</pub-id><pub-id pub-id-type="other">2-s2.0-85046266099</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teeuwssen</surname><given-names>M.</given-names></name><name><surname>Fodde</surname><given-names>R.</given-names></name></person-group><article-title>Cell heterogeneity and phenotypic plasticity in metastasis formation: the case of colon cancer</article-title><source><italic>Cancers</italic></source><year>2019</year><volume>11</volume><issue>14</issue><fpage>1368</fpage><pub-id pub-id-type="doi">10.3390/cancers11091368</pub-id><pub-id pub-id-type="other">2-s2.0-85073361408</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak-Sliwinska</surname><given-names>P.</given-names></name><name><surname>Scapozza</surname><given-names>L.</given-names></name><name><surname>Altaba</surname><given-names>A. R. I</given-names></name></person-group><article-title>Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer</article-title><source><italic>Biochimica et Biophysica Acta (BBA)-Reviews on Cancer</italic></source><year>2019</year><volume>1</volume></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcken</surname><given-names>R.</given-names></name><name><surname>Zimmermann</surname><given-names>M. O.</given-names></name><name><surname>Lange</surname><given-names>A.</given-names></name><name><surname>Joerger</surname><given-names>A. C.</given-names></name><name><surname>Boeckler</surname><given-names>F. M.</given-names></name></person-group><article-title>Principles and applications of halogen bonding in medicinal chemistry and chemical biology</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>2013</year><volume>56</volume><issue>18</issue><fpage>1363</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1021/jm3012068</pub-id><pub-id pub-id-type="other">2-s2.0-84874632186</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirimulla</surname><given-names>S.</given-names></name><name><surname>Bailey</surname><given-names>J. B.</given-names></name><name><surname>Vegesna</surname><given-names>R.</given-names></name><name><surname>Narayan</surname><given-names>M.</given-names></name></person-group><article-title>Halogen interactions in protein&#x2013;ligand complexes: implications of halogen bonding for rational drug design</article-title><source><italic>Journal of Chemical Information and Modeling</italic></source><year>2013</year><volume>53</volume><issue>19</issue><fpage>2781</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1021/ci400257k</pub-id><pub-id pub-id-type="other">2-s2.0-84888630744</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>Halogen bond: its role beyond drug&#x2013;target binding affinity for drug discovery and development</article-title><source><italic>Journal of Chemical Information and Modeling</italic></source><year>2014</year><volume>54</volume><issue>20</issue><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1021/ci400539q</pub-id><pub-id pub-id-type="other">2-s2.0-84893415560</pub-id></element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupton</surname><given-names>J. T.</given-names></name><name><surname>Burham</surname><given-names>B. S.</given-names></name><name><surname>Krumpe</surname><given-names>K.</given-names></name><etal /></person-group><article-title>Synthesis and cytotoxicity of 2, 4-disubstituted and 2, 3, 4-trisubstituted brominated pyrroles in murine and human cultured tumor cells</article-title><source><italic>Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry</italic></source><year>2000</year><volume>333</volume><issue>256</issue><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/(sici)1521-4184(200001)333:1&#x3c;3::aid-ardp3&#x3e;3.0.co;2-4</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>M. K.</given-names></name><name><surname>Alam</surname><given-names>S.</given-names></name><name><surname>Mirkovic</surname><given-names>J.</given-names></name><name><surname>Hossain</surname><given-names>M. F.</given-names></name></person-group><article-title>Screening of human proteins for fluoride and aluminum binding</article-title><source><italic>Bioinformation</italic></source><year>2018</year><volume>14</volume><issue>22</issue><fpage>68</fpage><pub-id pub-id-type="doi">10.6026/97320630014068</pub-id></element-citation></ref><ref id="B44" content-type="article"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salwiczek</surname><given-names>M.</given-names></name><name><surname>Nyakatura</surname><given-names>E. K.</given-names></name><name><surname>Gerling</surname><given-names>U. I.</given-names></name><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Koksch</surname><given-names>B.</given-names></name></person-group><article-title>Fluorinated amino acids: compatibility with native protein structures and effects on protein&#x2013;protein interactions</article-title><source><italic>Chemical Society Reviews</italic></source><year>2012</year><volume>41</volume><issue>23</issue><fpage>2135</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1039/c1cs15241f</pub-id><pub-id pub-id-type="other">2-s2.0-84857536069</pub-id></element-citation></ref><ref id="B45" content-type="book"><label>45</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Coenen</surname><given-names>H. H.</given-names></name><name><surname>Mertens</surname><given-names>J.</given-names></name><name><surname>Mazi&#xe8;re</surname><given-names>B.</given-names></name></person-group><source><italic>Radioionidation Reactions for Pharmaceuticals: Compendium for Effective Synthesis Strategies</italic></source><year>2006</year><publisher-loc>Berlin, Germany</publisher-loc><publisher-name>Springer Science &#x26; Business Media</publisher-name></element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>B. K.</given-names></name><name><surname>Ngaini</surname><given-names>Z.</given-names></name><name><surname>Matthew Neilsen</surname><given-names>P.</given-names></name><etal /></person-group><article-title>Synthesis and anticancer activities of 4-[(Halophenyl) diazenyl] phenol and 4-[(Halophenyl) diazenyl] phenyl aspirinate derivatives against nasopharyngeal cancer cell lines</article-title><source><italic>Journal of Chemistry</italic></source><year>2017</year><volume>2017</volume><issue>234</issue><pub-id pub-id-type="doi">10.1155/2017/6760413</pub-id><pub-id pub-id-type="other">2-s2.0-85027309424</pub-id></element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahu</surname><given-names>P. K.</given-names></name><name><surname>Sahu</surname><given-names>P. K.</given-names></name><name><surname>Sahu</surname><given-names>P. L.</given-names></name><name><surname>Agarwal</surname><given-names>D. D.</given-names></name></person-group><article-title>Structure activity relationship, cytotoxicity and evaluation of antioxidant activity of curcumin derivatives</article-title><source><italic>Bioorganic &#x26; Medicinal Chemistry Letters</italic></source><year>2016</year><volume>26</volume><issue>235</issue><fpage>1342</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.12.013</pub-id><pub-id pub-id-type="other">2-s2.0-84958118393</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosmann</surname><given-names>T.</given-names></name></person-group><article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title><source><italic>Journal of Immunological Methods</italic></source><year>1983</year><volume>65</volume><issue>480</issue><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(83)90303-4</pub-id><pub-id pub-id-type="other">2-s2.0-0021061819</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badisa</surname><given-names>R. B.</given-names></name><name><surname>Darling-Reed</surname><given-names>S. F.</given-names></name><name><surname>Joseph</surname><given-names>P.</given-names></name><name><surname>Cooperwood</surname><given-names>J. S.</given-names></name><name><surname>Latinwo</surname><given-names>L. M.</given-names></name><name><surname>Goodman</surname><given-names>C. B.</given-names></name></person-group><article-title>Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells</article-title><source><italic>Anticancer Research</italic></source><year>2009</year><volume>29</volume><issue>8</issue><fpage>2993</fpage><lpage>2996</lpage></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jitareanu</surname><given-names>A.</given-names></name><name><surname>Tataringa</surname><given-names>G.</given-names></name><name><surname>Zbancioc</surname><given-names>A.-M.</given-names></name><name><surname>Trifan</surname><given-names>A.</given-names></name></person-group><article-title>Bromination-a versatile tool for drugs optimization</article-title><source><italic>The Medical-Surgical Journal</italic></source><year>2018</year><volume>122</volume><issue>255</issue><fpage>614</fpage><lpage>626</lpage></element-citation></ref></ref-list></back></article>